The Syk kinase as a therapeutic target in leukemia and lymphoma.
about
Identification of type-II inhibitors using kinase structuresImidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP)A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint InflammationThe High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.B-cell receptor signaling as a driver of lymphoma development and evolution.The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLLTargeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.p110δ PI3 kinase pathway: emerging roles in cancer.Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinomaPharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.Quinoxaline derivatives: a patent review (2006--present).B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.Accelerated therapeutic progress in diffuse large B cell lymphoma.Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.Phenyl carboxamide analogues as spleen tyrosine kinase (syk) inhibitors.The promoter methylation of the Syk gene in nasopharyngeal carcinoma cell lines.Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment.Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.The status of fostamatinib in the treatment of rheumatoid arthritis.SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.
P2860
Q27681692-B2346B38-7C2E-4555-A477-875ACDC40C92Q27702174-46206E5F-4908-467E-BE1A-9238A2CD02A4Q28552367-E191779A-2147-4AEC-B3B5-4E5F41437A29Q33613335-A2B2EA22-FE6A-4A5F-9758-57345C7A3852Q34398579-C3C55EC6-6C21-4357-8BFC-9803FEF58001Q36150234-A0D366C2-C288-4E58-A408-DA70E12F61AEQ36404778-8B16DB6D-7AD9-4A38-9305-2B473C16B643Q36533710-46A5D293-A3BE-49DD-8FD0-E273BF629511Q36647928-7578E8A6-CE92-4E68-B8E2-FCE92AB181A0Q37535480-04BBC157-1A9A-4EC1-B583-F65D06F5BA70Q37596764-AC805AD9-93F0-4277-B12A-24E6B4E91F89Q38042737-B811306B-4A54-40CA-9B73-78CB9DEB9A28Q38124119-73CE2669-BD09-4292-A8DD-C333C00D2F21Q38174498-6383733F-1FC5-4093-B9D2-A11BB8BA67F3Q38189848-7FCC620E-EC8B-4F45-BA1C-4A22F1D6353DQ39781758-407D0411-343A-4106-B6B8-6649D9EF4E82Q41856646-CC861D35-DB55-43B1-8A0A-1F724DEE8ABBQ42182953-BC36C72E-A394-477D-ABF3-EABF08223F48Q46550877-A56C4D0B-433F-4199-BCBC-7505069FFBF5Q49887894-F1D859C5-D03E-4F25-AEB0-82859494BBB8Q50662692-B7A2C574-0181-4370-8D6F-BD1E8FA129E1Q51308912-1D0586F2-DB85-4DE8-A5D7-24394829A41CQ52699628-470D1C69-D8A9-4E82-AFE4-B719D5533D4A
P2860
The Syk kinase as a therapeutic target in leukemia and lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@en
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@nl
type
label
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@en
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@nl
prefLabel
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@en
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@nl
P2860
P1476
The Syk kinase as a therapeutic target in leukemia and lymphoma.
@en
P2093
Luca Laurenti
P2860
P304
P356
10.1517/13543784.2011.570329
P407
P577
2011-03-26T00:00:00Z